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Inhaled beta-stimulants - a study of
high-dose v. conventional-dose treatment in
asthmatic outpatients
P. G. BARDIN, J. R. JOUBERT
Summary
A randomised double-blind controlled trial was conducted in
o(der to compare pulmonary function and protective effects
of salbutamol 200 ~g v. 1 000 /-Lg by inhalation. Twenty-three
known asthmatics took part in the study for a period of 12
weeks. Pulmonary function tests were performed at home
(peak expiratory flow-rate (PEFR» and in the laboratory (vital
capacity (VC), forced expiratory volume in 1 second (FEV,)
and PEFR) before and after treatment. Bronchial responsive-
ness was measured as the provocative dose of histamine that
caused a decrease of 30% of the area under the flow-volume
curve (AFVEao) 90 minutes afler pre-treatment with the study
medication. The 20 patients (10 per treatment group) who
completed the study were comparable at base-line in respect
of physiological and pulmonary function measurements.
Median PEFR, FVC and FVC, did not differ between the
treatment groups for the duration of stUdy. Histamine chal-
lenge testing demonstrated a significant decrease in protec-
tion that was only seen after 8 weeks of treatment in the high-
dose group (P < 0,05). Changes in pulse rate, blood pressure
as well as side-effects were similar in the two groups. Thus
treatment with higher doses of .a-stimulants in outpatients
had no demonstrable advantage. A significant impairment of
the ability to protect against histamine-induced bronchocon-
striction was shown; this may relate to .a-receptor down-
regUlation and hence the development of tachyphylaxis.
S Air Med J 1991; 79: 655-659.
Conventional canisters of salbutamol (albuterol) in everyday
use provide 100 J..I.g of drug per actuation and are of proven
value in the treatment of asthma. I The use of higher doses of
the drug has been proposed,2,3 and in clinical practice patients
are frequently seen who are known to use more than the
recommended 200 ~g 4 times per day. These patients seldom
complain of side-effects and report a good subjective response
to an increase in dosage.4
Corris er al.' studied the dose-response to inhaled salbutamol
in increasing doses in patients with chronic airflow obstruction
and found a significant relationship, with the larger doses
having a longer duration of action. High doses of .a-stimulants
have also been used to good effect in acute asthma by nebuli-
sation and intermittent positive pressure breathing.6 However,
no studies have been done to assess the efficacy of increased
doses on an outpatient population and to attempt an assessment
of the response to a bronchoconstrictor, such as histamine, .
after use of normal and increased doses of salbutamol. The
development of sub-Sensitivity with long-term administration
of f3-stimulants has been described by Weber er al.,7 but there
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is a paucity of data on bronchial stability after long-term use
of higher doses.
An investigation was undertaken to determine if non-cumu-
lative administration of salbutamol would produce a dose-
related response in asthmatics, and confer protection against
histamine challenge at the time of maximal anticipated bron-
chodilation.
Patients and methods
Twenty-three patients, aged 18 - 65 years, participated in the
study. All had clinical asthma, a reversible decrease in forced
expiratory volume in 1 second (FEV l ) of ~ 70% of predicted
demonstrated previously and peak expiratory flow rate (PEFR)
variation > 20% demonstrated for 2 weeks before the study.
All patients also had at least 15% reversibility of their FEV1 in
response to a test dose of aerosolised bronchodilator (200 Ilg
salbutamol). Patients were excluded if they were allergic to
salbutamol, had had a respiratory infection within 1 month
before study, had a history of angina pectoris or cardiac
rhythm disturbances, diabetes mellitus, liver or kidney disease
and if they were pregnant.
All patients used conventional inhaled bronchodilators. Oral
.a-stimulants were stopped, but oral theophylline medication
and oral steroids were continued in the same doses. Excluded
during the study were patients who developed a respiratory
infection, those who required any change of medication and
patients who were non-eompliant.
All patients signed informed consent documents and the
study was approved by the Ethical Comminee of the Medical
Faculty of the University of Stellenbosch.
Study protocol
Patients attended the allergy clinic at fortnightly intervals
after all medication had been withheld for at least 6 hours.
The study protocol is illustrated in Table 1.
PEFR measurements
All patients were instructed in the use of a Wright peak flow
meter. After instruction patients were asked to demonstrate
proficiency for recording PEFR. If this was not satisfactorily
shown, the manoeuvre was again demonstrated followed by
patient demonstration and if necessary the procedure was
again repeated until PEFR was measured accurately by all
patients. At follow-up visits the patients' technique for
measuring PEFR was re-assessed and improved if not correct.
The patients recorded PEFR at home twice daily (morning
and evening) 10 minutes after inhaling the study medication,
i.e. 200 J..I.g or 1000 ~g in a double-blind fashion.
Clinical data
A history and physical examination were peformed in all
patients at every visit. Blood samples were taken for assessment
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TABLE i. PROTOCOL TO INVESTIGATE TREATMENT WITH DIFFERENT DOSES OF ,a-STIMULANTS
Week
First visit
(baseline I)
1 + 2
(baseline 11)
3 + 4
5 + 6
7 + 8
9 + 10
Last visit
Outpatient activity
Inhalation of l3-stimulants
(200 /Lg) and other usual
medication
PEFRs done
PEFRs done, side-effects
listed, study medication
used every 6 hours
As 3 + 4
As 3 + 4
As 3 + 4
Research activity·
Baseline histamine challenge
test after no treatment for 12
hours
Baseline pulmonary functions
and histamine challenge test
after 200 /Lg salbutamol
inhaled by both treatment
groups
Patients randomlsed to
treatment with salbutamol 200
/Lg or 1 000 /Lg (double-blirJd)t
Pulmonary function tests
before and after study
medication
Histamine challenge at 90 min
As for 3 + 4
As for 3 +4
As for 3 + 4
Diffusion test
". At the end of the 2~week period, except first visit
t Supplied by Glaxo Group Research, Greenford, Middlesex, UK.
of serum potassium (Kj and serum theophylline levels. Patients
reponed side-effects at home and after use of the medication
in the laboratory for a 9O-minute period.
Pulmonary functions
All pulmonary function measurements were performed on
an Elf pneumotac (computerised lung function system, Ob-
structive Pulmonary Disease Unit, Tygerberg Hospital) by the
same trained pulmonary technologist. Flow-volume curves
were obtained in every patient before and 60 minutes after use
of the medication. The forced vital capacity (FVC), FEV1and
PEFR were repeated until within 5% of another measurement,
the highest values peing used for analysis. Pulmonary function
measurements were done at specific times, as shown in
Table I.
Histamine challenge testing
Histamine challenge was performed at baseline I (no treat-
ment for 12 hours) and at baseline, II (90 minutes after
salbutamol 200 p.g in both groups). Patients then used the
study medication at home (200 p.g or 1000 p.g salbutamol) and
visited the laboratory every 2 weeks (weeks 4 - 10) for challenge
testing 90 minutes after pre-treatment with either 200 p.g or
1000 p.g salbutamol.
Histamine challenge testing was done according to the
method of Cockroft et al.,B utilising a DeVilbiss ultrasonic
nebuliser (DeVilbiss, Somerset, Pennsylvania, USA) with
graded increases in the histamine dosage of 0,03, 0,06, 0,125,
0,25, 0,5, 1,0, 2,0 and 4,0 mglml. Pulmonary function was
measured on a Collins dry-seal spirometer coupled .to a com-
puter that measured the area under the expiratory flow-
volume curve (AFVE).9 Measurements of a decrease of 30% of
the AFVE (AFVE30) have been shown to correlate closely with
a decrease of 20% in FEV1 on antigen challenge (PD20).lO It
has been used as an index of airway obstruction in various
other published studies. ll- 13 The challenge test was tenninated
when the AFVE had fallen below 30% of the initial value. A
minimum period of at least 6 minutes elapsed after completion
of one inhalation period and stan of the next. A histamine
challenge test was only performed if the initial AFVE was
within 80% of previous base-line measurements.
Diffusion test
Transfer factor (TL) was measured with a Morgan apparatus
(Morgan Instruments, Chatham, Kent, UK) by means of a
single breath helium-carbon monoxide dilution technique. The
mean of 3 test values was used and compared with predicted
normal values for every patient. The predicted normal values
used for spirometry and diffusion were as proposed. by
Schoenberg et a/.!4 and Cotes,15 respectively.
Statistical methods
PEFR, FEV1 and FVC were analysed as percentage of
predicted and also as absolute values. An initial examination of
the data by means of stem and leaf diagrams and distribution
curves showed a non-Gaussian distribution, and hence a non-
parametric test (Mann-Whimey V-test) was used to compare
median values.
Logarithmic transformation of the histamine AFVE30 was
used for statistical calculations. The treatment groups were
compared at baseline and at every 2-week period by the
Mann-Whimey V-test. Intragroup comparisons (e.g. comparing
week 10 with baseline or week 4, 6 or 8) werj;: done by
Wilcoxon's signed-rank test. All tests were two-t:;liled.
Results
Twenty-three asthmatic patients with mild-to-moderate airflow
obstruction were studied; 20 completed the study. Three
patients were withdrawn from the study because of intercurrent
respiratory infections or changes in medication. Baseline data
on the patients are shown in Table II. There were no significant
differences between the groups with regard to pulmonary
function or any of the other baseline measurements. ne
theophylline blood levels were therapeutic in all cases (10 - 20
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TABLE 11. BASELINE ANTHROPOMETRIC, PHYSIOLOGICAL AND TREATMENT DATA IN 20
. MODERATELY SEVERE ASTHMATIC PATIENTS
" Treatment groups
0,06
16 (19)
78,5 (22)
87 (20,5)
9,2 ± 3,6
8
5
1 000 p.g (N = 10)
31 + 10,6
M=1;F=9
0,125
15 (17)
87,5 (24)
80,0 (24)
9,0 ± 3,9
8
4
200 p.g (N = 10)
28 ± 8,7
M = 3; F = 7
Mean age ± SO (yrs)
sex
Mean duration of asthma ±
SO (yrs)
Skin tests positive
IgE raised (> 200 kUII)
FVC median % predicted
(Interquartlle range)
FEV1 median % predicted
(Interquartlle range)
Median % improvement FEY1
(Interquartlle range)·
AFVE30 (median dose)t
(mglml)
Diffusion - % predicted
(mean ± SO) 101 ± 2 98 ± 4
Medication T = 6, C = 3, 0 = 1 T = 8, C = 2
• After inhalation of 200 ,.g salbutamol.
t Median dose 01 histamine required at base-line lesting (without preceding treatmenllor 12 hours) 10 produce reduction of AFVE > 30%.
T = oral theophylline. C = oral corticosteroids, 0 = oral carboxymethylcysleine.
JLg/ml), except for 2 patients in the 200 Jig group who had low
levels at visit I and visit 3, respectively.
PEFR
The median values of PEFR measured during the period of
smdy after the double-blind use at home of the different doses
of bronchodilator are shown in Fig.!. There were no significant
differences between PEFRs measured by patients using con-
ventional doses compared with those treated with higher doses
of ,8-stimulants.
Change in FEV1IFVC after use of medication
Median values of the changes in FEV I measured after use of
the study medication are shown in Fig. 2. Changes in FVC
were also measured (data not shown). Both medication groups
showed an increase in FEV l and FVC after treatment but
these were not significantly different in the degree of broncho-
dilation achieved.
Histamine challenge testing
Comparison of the TWO treatment groups showed no signifi-
cant differences in their histamine sensitivity at baseline (Fig.
3). Significant protection against histamine was demonstrated
by 200 Jig salbutamol administered to both groups (baseline
II) when compared with baseline histamine challenge without
pre-treatment for at least 12 hours (baseline I). Both groups
thus demonstrated a significant decrease in sensitivity to
histamine, as could be expected after pre-treatment with ,8-
stimulants (P < 0,02). No significant differences were noted in
AFVE30 between the groups at baseline II (week 2) or at
weeks 4, 6 and 8. However, at week 10 a difference in
histamine sensitivity had developed beTWeen the two treatment
groups that almost reached statistical significance (P < 0,06).
This was attributable to an increase in histamine sensitivity in
the I 000 Jig group.
The 200 Jig group had stable AFVE30 values over the study
period (Fig. 3). This was in contrast with the I 000 Jig group,
which demonstrated a gradual decrease in AFVE30 at weeks 6
and 8 and which became statistically significant at week 10 (P
< 0,05) when compared with week 4 but not when compared
with week 2. Protection against histamine was thus decreased
after treatment with a higher dose for 8 weeks when compared
with protection after only 2 weeks of treatment. Although it
could not be demonstrated statistically, treatment after 4
weeks appeared to give more protection against histamine than
was found at week 2. However, this improved protection
decreased gradually to be significantly lowered at we'~k 10
(Fig. 3).
When histamine sensitivity was assessed as change from
baseline I there was less change in the 1000 Jig group (com-
pared with the 200 Jig group) at week 8. This difference just
failed to reach statistical significance at week 10 (P < 0,06). It
confmns the decrease in protection afforded by I 000 Jig of
salbutamol at the 10th week.
Side-effects
Side-effects were similar in both groups, tremor being
reported most frequently. Measurement of baseline and
follow-up serum potassium values were normal in both groups.
After treatment in the laboratory there were no differences in
pulse rate and blood pressure between the two treatment
groups.
Discussion
This smdy did not show any significant advantage for the use
of higher doses of ,8-stimulant inhalation in patients with
moderate-to-severe asthma. Assessment of symptoms, PEFR
and regular pulmonary functions in the laboratory did not
detect any differences between treatment with conventional
doses and higher doses. A possible decrease in protection in
the high-dose group against a bronchoconstrictor (histamine)
was only manifest after 8 weeks of treatment.
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Fig. 3. Effect of 200 /ig salbutamol (solid circle) and 1000 /i9
salbutamol (open circle) on geometric mean histamine AFVE30
over a period of 8 weeks. Arrow indicates start of treatment
period. Baseline I represents values after no pre-treatment and
baseline 11 values after inhalation of 200 /ig salbutamol by both
treatment groups.
Nelson et a/. 16 demonstrated a linear relationship between
increasing doses of albuterol (salbutamol) and increased FEV,
by measuring the response to I, 2, 4, 6 and 8 consecutive
inhalations. With some exceptionsp most in vivo studies have
shown that there is indeed a linear correlation between the log
dose of bronchodilator and the response of the airways. 18-20
However, Riley et aUl showed an enhanced bronchodilator
response to isoproterenol by sequential administration of the
drug in divided doses. They then failed to demonstrate increas-
ing bronchodilatation after single inhalations of this ~-stimu­
lant. Our fmdings could thus have been the result of the use of
two inhalations of a high dose instead of multiple inhalations.
From a practical point of view, the results found in the
laboratory may not be achieved in an outpatient-based study
when asthmatics use the current practical method of inhaling
bronchodilators. Only two 'puffs' from a higher-dose broncho-
dilator may therefore not be better than standard treatment
with the usual doses. An alternative possibility for the lack of
response may be that PEFR and FEV1 responses were on the
plateau part of the dose-response curve. This is supported by
the absence of a difference in side-effeets between the two
treatment groups. Decreased protection may consequently be
more apparent on histamine challenge than in changes in
FEV!> FVC or PEFR. -
This study assessed pulmonary function and bronchodilation
by means of the FVC, FEV1and PEFR; other more sensitive
measurements might conceivably have shown different results.
However, Popa and Werner22 demonstrated that measurement
of the above parameters was adequate to show a significant log
dose-response in 15 patients, and most other studies of this
nature have not had participation of more than 20 p~iients.7.16-18
We found a significant decrease in protection agaiDst hista-
mine-induced bronchoconstriction in the high-dose salbutamol
treatment group' after daily use of the medication for 8 weeks.
This decrease was clearly demonstrable after 10 weeks com-
pared with that found after 2 weeks of treatment (week 4).
Relative to treatment with 200 p.g, there was also decreased
protection at week 10, although this difference jlist failed to
reach statistical significance. There were no clear differences
noted in the 1()()() p.g group for week 2 (after 200 p.g sal-
butamol) compared with week 10, implying that protection
may have been increased at week 4 and that it had gradually
decreased until week 10. A parallel decrease in PEFR, FEV1
and FVC at 10 weeks could not be demonstrated. A similar
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Fig. 1. Median PEFR for 16 patients measured after use of /3-
stimulant inhalation for 8 consecutive weeks. Absolute values are
shown. Each box with bars represents the interquartile area and
median' of every group with maximum and minimum values.
Patients used either 200 /ig or 1 000 /ig salbutamol - 8 patients
per group. PEFRs from 4 patients were incomplete and are not
included in analysis. Unshaded boxes represent morning values
and shaded boxeS' represent evening values. No statistical dif-
ferences were noted (P> O,OS).
Fig. 2. Median bronchodilator response (change in FEY,) to
inhalation of either 200 /ig salbutamol (10 patients) or 1000 /ig
salbutamol (10 patients). Absolute values are shown. Measure-
ments were done every 2 weeks. No significant differences were
detected between the two groups.
~menuation of the degree of protection conferred by higher
(ioses of ,a-stimulants was found by Vathenen er aP3 in 8
patients after .only 14 days. Their study differed in design
from ours, which may account for the reduction in protection
<lbserved after only 2 weeks of treatment found in that study.
~fhe major effect in their study was seen some 23 hours after
the last dose. Peel and Gibson24 failed to show decreased
I'rotection against conventional doses of salbutamol given by
:cterosol, a fmding which is consistent with our results.
Possible causes for the decrease in protection include the
cievelopment of tachyphylaxis or the intriguing possibility
Ilroposed by Tattersfield and others that treatment by ,a-
stimulants may lead to the developmeilt of hyperreactivity in
gsthmatics.23 No further data on the latter are available,
glthough Reisman25 demonstrated that asthma can be aggra-
vated by adrenergic aerosol overuse. The study of tachyphylaxis
in asthma is fraught with problems.26 Cenain precautions
must be observed, including a suitable 'wash-out' period to
remove pre-existing tachyphylaxis from previous medication.
A further confounding variable may ·be the effect of other
medication, such as theophylline and corticosteroids.26 Our
study included a modified 'wash-out' period of 2 weeks during
which only ,a-stimulant inhalation, theophylline and steroids
were used, and thereafter all medication was unchanged except
for ,a-stimulants. The gradual development of decreased pro-
tection in the 1000 Jlg group and the 'relative stability of the
zOO Jlg group suggests that tachyphylaxis may have developed.
It appears unlikely for other medication to explain the results,
because the two treatment groups were taking almost identical
medication and this '.Vas unchanged for the duration of study.
If histamine provocation had been continued after the initial
provocation done 90 minutes after treatment, decreased pro-
tection may have been demonstrable at an earlier stage. Con-
versely, it would have been interesting to see if the decrease at
10 weeks continued and became worse after further treatment
with high doses of salbutamol.
The observation that higher-dose therapy with inhaled sal-
butamol rendered patients more vulnerable to histamine and
appeared to diminish the protective effect of medication needs
to be considered for its practical implications. Regular high-
dose administration may not only prove to be cost-ineffective,
but could possibly deprive asthmatics' of the full efficacy of
salbutamol prophylaxis and treatment. Our fmdings have to be
confirmed in other outpatient-based' studies to assess the
clinical imponance in the treatment of asthma.
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